申请人:Chemocentryx, Inc.
公开号:US07786157B2
公开(公告)日:2010-08-31
The present invention provides compounds having formula (I):
or pharmaceutically acceptable salts and N-oxides thereof, wherein the subscript m is an integer from 0-4; Ar is an optionally substituted aryl; B is an optionally substituted aryl; L1 is an optionally substituted linking group selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and —CH2N(Ru)X5—; and L2 is a bond or C1-3 alkylene. The compounds act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity.
本发明提供具有式(I)的化合物或其药学上可接受的盐和N-氧化物,其中下标m是0-4的整数;Ar是可选取的取代芳基;B是可选取的取代芳基;L1是从C1-4烷基,C1-4杂环烷基,C2-4烯基和-CH2N(Ru)X5-等组中选择的可选取的取代连接基;L2是键或C1-3烷基。这些化合物作为CCR1受体的有效拮抗剂,并具有体内抗炎活性。